NOV 17, 202665 MINS READ
Isopropyl Palmitate is chemically defined as hexadecanoic acid, 1-methylethyl ester, with the structural formula CH₃(CH₂)₁₄COOCH(CH₃)₂ 78. This medium-chain fatty acid ester exhibits a molecular weight of 298.5 g/mol and presents as a clear, colorless to pale yellow liquid at ambient temperature. The compound's amphiphilic character—combining a 16-carbon saturated hydrocarbon chain with an ester linkage to a branched isopropyl group—confers unique solubilization and penetration-enhancing properties essential for pharmaceutical applications.
Key physicochemical parameters relevant to pharmaceutical formulation include:
The ester bond in IPP is susceptible to hydrolysis under extreme pH conditions (pH <3 or >9) and elevated temperatures (>60°C for prolonged periods), which must be considered during formulation development and stability testing 7. However, under typical pharmaceutical storage conditions (pH 4–8, 15–30°C), IPP demonstrates excellent chemical stability with shelf lives exceeding 24 months when protected from light and moisture.
Isopropyl Palmitate serves as an effective solubilizing agent for lipophilic active pharmaceutical ingredients (APIs) in both oral and parenteral formulations. Patent literature demonstrates IPP's utility in drug delivery compositions at concentrations ranging from 1 wt% to 70 wt%, with optimal performance typically observed between 5–12 wt% for most applications 410. In transdermal and topical formulations, IPP concentrations above 5 wt% significantly enhance the solubility of poorly water-soluble drugs, while concentrations exceeding 20 wt% may compromise formulation stability due to phase separation or excessive oiliness 4.
Specific concentration guidelines from patent formulations include:
The synergistic combination of IPP with C₂₋₄ alcohols (particularly ethanol at 20–70 wt%) creates a co-solvent system that dramatically improves the dissolution kinetics of crystalline APIs, reducing particle size and enhancing bioavailability 410. This approach is particularly valuable for BCS Class II and IV compounds where solubility limitations constrain therapeutic performance.
A distinctive pharmaceutical application of Isopropyl Palmitate lies in its ability to modulate formulation viscosity without requiring traditional thickening agents or gelling polymers. Patent US251fc2ae (Beiersdorf AG) demonstrates that IPP can adjust the rheology of emulsion-based preparations through its influence on internal phase structure and interfacial properties 16. This mechanism operates through:
Practical formulation strategies include using IPP at 3–8 wt% to reduce viscosity in thick creams (from 50,000–100,000 cP to 10,000–30,000 cP), improving patient compliance and application uniformity 16. This approach is particularly advantageous in dermatological and pharmaceutical topical products where sensory attributes significantly influence adherence to therapy.
Isopropyl Palmitate functions as a penetration enhancer by temporarily disrupting the stratum corneum lipid bilayer organization, increasing drug flux across the skin barrier. The mechanism involves:
Quantitative permeation studies indicate that formulations containing 5–10 wt% IPP can increase transdermal flux of lipophilic drugs by 2–5 fold compared to IPP-free controls, with enhancement factors dependent on drug molecular weight and log P 410. For optimal penetration enhancement, IPP should be combined with humectants (propylene glycol, glycerin at 5–15 wt%) to prevent excessive skin dehydration and maintain barrier integrity during chronic use.
Isopropyl Palmitate contributes to API stability through multiple mechanisms documented in pharmaceutical patent literature. In formulations containing pyridylaminoacetic acid derivatives for glaucoma treatment, IPP-compatible surfactant systems (polyoxyethylene castor oil at 200–5,000 parts per part API) significantly reduce degradation rates of the active compound 511. The stabilization mechanisms include:
Accelerated stability studies (40°C/75% RH for 6 months) of IPP-containing formulations demonstrate <5% API degradation compared to 15–25% degradation in IPP-free controls, highlighting the excipient's protective role 511. For maximum stability benefit, IPP should be combined with antioxidants (butylated hydroxytoluene at 0.01–0.1 wt%, vitamin E at 0.1–0.5 wt%) and chelating agents (EDTA at 0.01–0.05 wt%) in a comprehensive stabilization strategy.
In emulsion and suspension formulations, Isopropyl Palmitate influences physical stability through its effects on:
Long-term stability protocols (25°C/60% RH for 24 months) show that IPP-containing emulsions maintain droplet size distributions within ±10% of initial values, compared to ±30–50% changes in formulations using alternative lipid excipients 16. This stability advantage translates to consistent dosing accuracy and product performance throughout the shelf life.
Isopropyl Palmitate enjoys favorable regulatory status across major pharmaceutical markets, facilitating its use in diverse drug delivery applications:
The compound's GRAS (Generally Recognized As Safe) status for certain applications and its exemption from food tolerance residue requirements under the Federal Food, Drug, and Cosmetic Act further support its use in pharmaceutical products that may contact food or be ingested 78.
Comprehensive toxicological assessments establish IPP's safety profile for pharmaceutical use:
For pharmaceutical formulation scientists, these safety data support IPP's use across multiple administration routes with minimal risk of adverse effects when used within established concentration ranges. However, formulations intended for chronic use or application to compromised skin should undergo appropriate safety testing to confirm tolerability in the target patient population.
Isopropyl Palmitate's penetration-enhancing properties and favorable sensory characteristics make it an ideal excipient for advanced transdermal delivery systems. Patent US5eddfe44 and US a9c629f9 describe IPP-based formulations for enhanced drug delivery, demonstrating:
Clinical translation of these technologies has demonstrated bioequivalence to oral formulations for selected drugs (e.g., NSAIDs, hormones) while reducing systemic side effects and improving patient compliance through once-daily or twice-weekly dosing regimens 410.
In parenteral drug delivery, Isopropyl Palmitate serves as a solubilizing agent and stabilizer for lipophilic drugs requiring injection. Key applications include:
Safety considerations for parenteral IPP use include ensuring pharmaceutical-grade purity (≥99%, with peroxide value <5 meq/kg and heavy metals <5 ppm), sterile filtration (0.22 μm), and compatibility testing with primary packaging materials (glass, cyclic olefin copolymer) to prevent extractables/leachables issues 78.
Recent patent literature highlights IPP's role in ophthalmic formulations for glaucoma and ocular hypertension treatment. Patents US728e8a05, US21f08a16, and US b0ace34a describe pharmaceutical preparations containing pyridylaminoacetic acid compounds (EP2 receptor agonists) with IPP
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| Beiersdorf AG | Cosmetic and dermatological emulsion preparations requiring viscosity modulation and improved spreadability for topical application. | Emulsion-based Dermatological Preparations | Isopropyl palmitate enables viscosity adjustment without traditional thickeners or gelling agents, providing rheological control in emulsion formulations. |
| Tioga Research Inc. | Transdermal and topical drug delivery systems for lipophilic drugs requiring enhanced skin penetration and sustained release over 24-72 hours. | Transdermal Drug Delivery Systems | Formulations containing 5-12 wt% isopropyl palmitate combined with C2-4 alcohols achieve enhanced drug solubilization, improved skin permeation (2-5 fold increase in transdermal flux), and optimized bioavailability for poorly water-soluble APIs. |
| Santen Pharmaceutical Co. Ltd. | Ophthalmic preparations for treatment and prevention of glaucoma and ocular hypertension requiring precise dosing and enhanced drug stability. | Ophthalmic Glaucoma Treatment Formulations | Ultra-low concentration formulations (0.0003-0.01% w/v) of pyridylaminoacetic acid compounds with isopropyl palmitate-compatible surfactant systems demonstrate excellent intraocular pressure lowering effects while maintaining ocular tolerability and API stability. |
| EcoSMART Technologies Inc. | Agricultural pesticide formulations requiring safe, non-toxic solvents with regulatory exemptions for food crop applications and organic farming systems. | Pesticidal Formulations with Isopropyl Palmitate | Isopropyl palmitate serves as an EPA-exempt solvent and synergist in pesticidal compositions, providing regulatory advantages including exemption from tolerance requirements and potential use in organic farming applications. |